首页> 外文期刊>American Journal of Transplantation >Anti-TCRβ mAb Induces Long-Term Allograft Survival by Reducing Antigen-Reactive T Cells and Sparing Regulatory T Cells
【24h】

Anti-TCRβ mAb Induces Long-Term Allograft Survival by Reducing Antigen-Reactive T Cells and Sparing Regulatory T Cells

机译:抗TCRβmAb通过减少抗原反应性T细胞并节省调节性T细胞诱导同种异体移植的长期存活

获取原文
获取原文并翻译 | 示例
           

摘要

TCR specific antibodies may modulate the TCR engagement with antigen–MHC complexes, and in turn regulate in vivo T cell responses to alloantigens. Herein, we found that in vivo administration of mAbs specific for mouse TCRβ (H57–597), TCR or CD3 promptly reduced the number of CD4+ and CD8+ T cells in normal mice, but H57–597 mAb most potently increased the frequency of CD4+Foxp3+ Treg cells. When mice were injected with staphylococcal enterotoxin B (SEB) superantigen and H57–597 mAb, the expansion of SEB-reactive Vβ8+ T cells was completely abrogated while SEB-nonreactive Vβ2+ T cells remained unaffected. More importantly, transient H57–597 mAb treatment exerted long-lasting effect in preventing T cell responses to alloantigens, and produced long-term cardiac allograft survival (>100 days) in 10 out of 11 recipients. While Treg cells were involved in maintaining donor-specific long-term graft survival, T cell homeostasis recovered over time and immunity was retained against third party allografts. Moreover, transient H57–597 mAb treatment significantly prolonged survival of skin allografts in na?ve recipients as well as heart allografts in skin-sensitized recipients. Thus, transient modulation of the TCRβ chain by H57–597 mAb exhibits potent, long-lasting therapeutic effects to control alloimmune responses.
机译:TCR特异性抗体可能会调节TCR与抗原-MHC复合物的结合,进而调节体内T细胞对同种抗原的反应。在这里,我们发现,体内施用对小鼠TCRβ(H57–597),TCR或CD3特异的mAb可迅速减少CD4 + 和CD8 + T细胞的数量正常小鼠,但H57–597 mAb最有效地增加了CD4 + Foxp3 + Treg细胞的频率。当给小鼠注射葡萄球菌肠毒素B(SEB)超抗原和H57–597 mAb时,SEB反应性Vβ8 + T细胞的扩增被完全消除,而SEB不反应性Vβ2 + T细胞不受影响。更重要的是,瞬时H57-597 mAb治疗在预防T细胞对同种抗原的反应中发挥了长效作用,并在11位接受者中有10位产生了长期的心脏异体移植存活(> 100天)。尽管Treg细胞参与维持供体特异性长期移植物的存活,但T细胞稳态却随着时间的推移而恢复,并且保留了针对第三方同种异体移植物的免疫力。此外,短暂的H57–597 mAb治疗可显着延长幼稚受体皮肤同种异体移植的存活时间,以及皮肤敏感受体心脏同种异体移植的存活时间。因此,H57–597 mAb对TCRβ链的瞬时调节表现出有效,持久的治疗效果,可控制同种免疫反应。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号